# A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer

> **NCT07401381** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Rovi Pharmaceuticals Laboratories** · enrollment: 120 (estimated)

## Conditions studied

- Hormone Receptor Positive Early Breast Cancer

## Interventions

- **DRUG:** US-sourced oral Femara® + Letrozole SIE
- **DRUG:** EU sourced oral Femara® + Letrozole SIE

## Key facts

- **NCT ID:** NCT07401381
- **Lead sponsor:** Rovi Pharmaceuticals Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2028-05
- **Final completion:** 2028-10
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07401381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07401381, "A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07401381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*